| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |





From the Departments of Neurosurgery*
and
Neuropathology,
University of Bonn Medical
Center, Bonn, Germany; the Department of
Neuropathology,
Heinrich-Heine-University,
Düsseldorf, Germany; the Institute of Human
Genetics,
Ruprecht-Karls-University,
Heidelberg, Germany; the Department Organization of Complex
Genomes,¶
German Cancer Research Center,
Heidelberg, Germany; and the Department of Pathology,||
Division of Molecular Histopathology, Addenbrookes Hospital,
Cambridge, United Kingdom
We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppressor genes CDKN2A (p16INKa/MTS1), p14ARF, CDKN2B (p15INK4b/MTS2) (all located at 9p21) and CDKN2C (1p32). Comparative genomic hybridization and microsatellite analysis showed losses on 1p in 11 anaplastic meningiomas (85%), 23 atypical meningiomas (68%), and 5 benign meningiomas (25%). One atypical meningioma with loss of heterozygosity on 1p carried a somatic CDKN2C mutation (c.202C>T: R68X). Losses on 9p were found in five anaplastic meningiomas (38%), six atypical meningiomas (18%), and one benign meningioma (5%). Six anaplastic meningiomas (46%) and one atypical meningioma (3%) showed homozygous deletions of the CDKN2A, p14ARF, and CDKN2B genes. Two anaplastic meningiomas carried somatic point mutations in CDKN2A (c.262G>T: E88X and c.262G>A: E88K) and p14ARF (c.305G>T: G102V and c.305G>A: G102E). One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14ARF, or CDKN2B lacked detectable transcripts from at least one of these genes. Hypermethylation of CDKN2A, p14ARF, and CDKN2B could be demonstrated in one of these cases. Taken together, our results indicate that CDKN2C is rarely altered in meningiomas. However, the majority of anaplastic meningiomas either show homozygous deletions of CDKN2A, p14ARF, and CDKN2B, mutations in CDKN2A and p14ARF, or lack of expression of one or more of these genes. Thus, inactivation of the G1/S-phase cell-cycle checkpoint is an important aberration in anaplastic meningiomas.
This article has been cited by other articles:
![]() |
D. Haase, S. Schmidl, C. Ewald, R. Kalff, C. Huebner, R. Firsching, G. Keilhoff, M. Evert, W. Paulus, D. H. Gutmann, et al. Fatty acid synthase as a novel target for meningioma therapy Neuro Oncology, February 5, 2010; (2010) noq004v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Solomon, J.-S. Kim, W. Jean, and T. Waldman Conspirators in a Capital Crime: Co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in Glioblastoma Multiforme Cancer Res., November 1, 2008; 68(21): 8657 - 8660. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Morrison, H. Satoh, J. Foley, J. L. Horton, J. K. Dunnick, G. E. Kissling, and D. E. Malarkey N-ethyl-N-nitrosourea (ENU)-Induced Meningiomatosis and Meningioma in p16INK4a/p19ARF Tumor Suppressor Gene-Deficient Mice Toxicol Pathol, October 1, 2007; 35(6): 838 - 845. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Maillo, A. Orfao, A. B. Espinosa, J. M. Sayagues, M. Merino, P. Sousa, M. Lara, and M. D. Tabernero Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone Neuro Oncology, October 1, 2007; 9(4): 438 - 446. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Pasmant, I. Laurendeau, D. Heron, M. Vidaud, D. Vidaud, and I. Bieche Characterization of a Germ-Line Deletion, Including the Entire INK4/ARF Locus, in a Melanoma-Neural System Tumor Family: Identification of ANRIL, an Antisense Noncoding RNA Whose Expression Coclusters with ARF Cancer Res., April 15, 2007; 67(8): 3963 - 3969. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Marx and W. F. Simonds Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes Endocr. Rev., August 1, 2005; 26(5): 615 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Cuevas, A. L. Slocum, P. Jun, J. F. Costello, A. W. Bollen, G. J. Riggins, M. W. McDermott, and A. Lal Meningioma Transcript Profiles Reveal Deregulated Notch Signaling Pathway Cancer Res., June 15, 2005; 65(12): 5070 - 5075. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sadetzki, P. Flint-Richter, S. Starinsky, I. Novikov, Y. Lerman, B. Goldman, and E. Friedman Genotyping of Patients with Sporadic and Radiation-Associated Meningiomas Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 969 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Hill, M. S. Linet, P. M. Black, H. A. Fine, R. G. Selker, W. R. Shapiro, and P. D. Inskip Meningioma and schwannoma risk in adults in relation to family history ofcancer Neuro Oncology, October 1, 2004; 6(4): 274 - 280. [Abstract] [PDF] |
||||
![]() |
V P Collins Brain tumours: classification and genes J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(suppl_2): ii2 - ii11. [Full Text] [PDF] |
||||
![]() |
M. A. Watson, D. H. Gutmann, K. Peterson, M. R. Chicoine, B. K. Kleinschmidt-DeMasters, H. G. Brown, and A. Perry Molecular Characterization of Human Meningiomas by Gene Expression Profiling Using High-Density Oligonucleotide Microarrays Am. J. Pathol., August 1, 2002; 161(2): 665 - 672. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |